Overview

Degludec Glargine U300 Hospital Study

Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
Limited data exist about the use of insulin degludec and insulin glargine U300 in the hospitalized patients. A previous study compared the safety and efficacy of insulin degludec versus insulin glargine U100 for the management of hospitalized patients with type 2 diabetes. However, there is no data comparing the efficacy and safety of insulin degludec versus insulin glargine U300 for the management of hospitalized patients with type 2 diabetes. Accordingly, the proposed study will provide a clinically useful information on the efficacy (blood glucose control) and safety (hypoglycemia) of insulin degludec versus insulin glargine U300 for the management of hospitalized patients with type 2 diabetes.
Phase:
N/A
Details
Lead Sponsor:
Medanta, The Medicity, India
Treatments:
Insulin Glargine